In research,

we go
further
together

We’re exploring an investigational treatment for ATTR amyloidosis, where you’re not just part of the study— YOU help lead the way

See if you qualify for TRITON‑PN

Introducing the TRITON‑PN study

TRITON-PN is a clinical research study for individuals who have hereditary ATTR amyloidosis with polyneuropathy.

TRITON-PN is a phase 3 study to:

Learn more about hereditary ATTR amyloidosis with polyneuropathy

Study an investigational medication called nucresiran

The TRITON-PN team will give study participants either nucresiran or vutrisiran, an approved medication for the treatment of amyloidosis. They want to see how nucresiran works when compared to vutrisiran. They also want to see how nucresiran works when compared to a placebo (a placebo is a substance that looks like the investigational medication but has no active ingredients).

There is no placebo in this study. Doctors will look at how participants respond to nucresiran and compare it to a group that received placebo in an earlier study.

What is the purpose
of this study?

This study is being done to find out if nucresiran can affect nerve health and reduce the symptoms of neuropathy in people with hereditary ATTR amyloidosis with polyneuropathy.

Researchers also want to see how nucresiran affects the quality of life of people living with this condition.

Can I be in the
TRITON-PN study?

You could be eligible for this study if you:

Are 18 to 85 years old
Have hereditary ATTR amyloidosis (confirmed through genetic testing) with polyneuropathy

Additional criteria may apply. See if you qualify for TRITON-PN

Study timeline

Screening Period

Up to 45 days

Assessments and procedures to see if you can be in the study

Treatment Period

18 months

Assessments and procedures to learn about nucresiran
Study visits every 3 months (a few visits will happen more often)

Treatment Extension Period

Up to 18 months

Assessments and procedures to learn about nucresiran
Study visits will vary every 3 to 6 months

Follow-up Period

Up to 12 months
(24 months for individuals who are able to become pregnant)

Assessments and procedures to monitor your health after you finish taking nucresiran
Study visits every 6 months

You can expect to be in the study for about 50 months (a little more than 4 years), or up to 62 months for individuals who are able to become pregnant.

What to expect in TRITON-PN

The TRITON-PN study
happens in 4 parts.

In the Screening Period, we'll determine if you're eligible for the study
In the Treatment Period, you'll receive either nucresiran or vutrisiran. You'll have a 4 out of 5 chance of receiving nucresiran, and a 1 out of 5 chance of receiving vutrisiran
In the Treatment Extension Period, you'll receive nucresiran
In the Follow-up Period, our study team will keep an eye on your health

Remember, there is no placebo in this study. You will receive either nucresiran or vutrisiran in the Treatment Period, and all participants will receive nucresiran in the Treatment Extension Period.